YPEL3 (Yippee-like 3) is a member of the evolutionarily conserved Yippee protein family, initially identified through homology to the *Drosophila* Yippee gene. This family is implicated in diverse cellular processes, including cell cycle regulation, differentiation, and apoptosis. The YPEL3 gene encodes a 15 kDa protein localized primarily in the nucleus and cytoplasm, though its precise molecular mechanisms remain under investigation. Studies suggest YPEL3 plays a role in cellular senescence and tumor suppression. It is frequently downregulated in cancers such as colorectal, breast, and hepatocellular carcinoma, correlating with poor prognosis, potentially due to its involvement in p53-mediated pathways or inhibition of epithelial-mesenchymal transition (EMT).
YPEL3 antibodies are essential tools for detecting and characterizing the protein’s expression, localization, and interactions in both normal and pathological contexts. Polyclonal or monoclonal antibodies targeting specific YPEL3 epitopes are utilized in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to explore its tissue distribution and functional roles. Recent research highlights YPEL3's potential as a biomarker for cancer progression or therapeutic response. However, challenges persist in standardizing antibody specificity across experimental models, necessitating rigorous validation. Ongoing studies aim to clarify YPEL3's regulatory networks and its utility in diagnostic or therapeutic strategies, emphasizing its emerging significance in cancer biology and cellular homeostasis.